WO2008104062A3 - Selective release of pro-apoptotic bcl-2 family members and their contribution to the bystander effect - Google Patents

Selective release of pro-apoptotic bcl-2 family members and their contribution to the bystander effect Download PDF

Info

Publication number
WO2008104062A3
WO2008104062A3 PCT/CA2008/000360 CA2008000360W WO2008104062A3 WO 2008104062 A3 WO2008104062 A3 WO 2008104062A3 CA 2008000360 W CA2008000360 W CA 2008000360W WO 2008104062 A3 WO2008104062 A3 WO 2008104062A3
Authority
WO
WIPO (PCT)
Prior art keywords
contribution
pro
family members
apoptotic bcl
selective release
Prior art date
Application number
PCT/CA2008/000360
Other languages
French (fr)
Other versions
WO2008104062A2 (en
Inventor
Mareck Los
Original Assignee
Univ Manitoba
Mareck Los
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba, Mareck Los filed Critical Univ Manitoba
Publication of WO2008104062A2 publication Critical patent/WO2008104062A2/en
Publication of WO2008104062A3 publication Critical patent/WO2008104062A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Abstract

Herein described is a method of sensitizing a population of cells to radiotherapy or chemotherapy or of inducing cell death by administering to the population of cells an effective amount of a purified or isolated Bax protein or a biologically active fragment thereof.
PCT/CA2008/000360 2007-02-27 2008-02-27 Selective release of pro-apoptotic bcl-2 family members and their contribution to the bystander effect WO2008104062A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89179207P 2007-02-27 2007-02-27
US60/891,792 2007-02-27

Publications (2)

Publication Number Publication Date
WO2008104062A2 WO2008104062A2 (en) 2008-09-04
WO2008104062A3 true WO2008104062A3 (en) 2008-10-30

Family

ID=39721638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2008/000360 WO2008104062A2 (en) 2007-02-27 2008-02-27 Selective release of pro-apoptotic bcl-2 family members and their contribution to the bystander effect

Country Status (1)

Country Link
WO (1) WO2008104062A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116144725B (en) * 2023-04-19 2023-06-20 青岛大学附属医院 Application of marine organism polypeptide in preparing anesthetic auxiliary drug

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022594A1 (en) * 2000-07-11 2002-02-21 Ping Dou Bax fragment induced tumor cell death
US20030215323A1 (en) * 2002-05-14 2003-11-20 Prinz Friedrich B. Micro gas turbine engine with active tip clearance control

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022594A1 (en) * 2000-07-11 2002-02-21 Ping Dou Bax fragment induced tumor cell death
US20030215323A1 (en) * 2002-05-14 2003-11-20 Prinz Friedrich B. Micro gas turbine engine with active tip clearance control

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PAOLONI-GIACOBINO A. ET AL.: "Evolutionary Appearance of Mononucleotide Repeats in the Coding Sequences of Four Genes in Primates", JOURNAL OF GENETICS, vol. 86, no. 3, December 2007 (2007-12-01), pages 279 - 283 *
SIMONEN M. ET AL.: "The BH3 Domain of Bax is Sufficient for interaction of Bax with Itself and with other Family Member and it is Required for Induction of Apoptosis", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 249, no. 1, 1 October 1997 (1997-10-01), pages 85 - 91, XP000882824 *
SUGIMOTO C. ET AL.: "Apoptosis-Promoting Gene (bax) Transfer Potentiates Sensitivity of Squamous Cell Carcinoma to Cisplatin In Vitro and In Vivo", INTERNATIONAL JOURNAL OF CANCER, vol. 82, no. 6, 9 September 1999 (1999-09-09), pages 860 - 867 *
ZHENG J.-Y. ET AL.: "Overexpression of Bax Induces Apoptosis and Enhances Drug Sensitivity of Hepatocellular Cancer-9204 Cells", WORLD JOURNAL OF GASTROENTEROLOGY, vol. 11, no. 23, 21 June 2005 (2005-06-21), pages 3498 - 3503 *

Also Published As

Publication number Publication date
WO2008104062A2 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
Gkikas et al. The role of mitophagy in innate immunity
EP3587558A3 (en) Methods of populating a gastrointestinal tract
Frasca et al. Gelatin tannate reduces the proinflammatory effects of lipopolysaccharide in human intestinal epithelial cells
WO2007065010A3 (en) Anti-angiogenesis compounds
WO2007022030A3 (en) Methods and compositions for the efficient delivery of therapeutic agents to cells and animals
BRPI0512146A (en) methods for treating an endobronchial infection in a patient, and a patient with cystic fibrosis, suffering from an endobronchial infection
WO2007138116A3 (en) Pharmaceutical composition for the treatment of viral infections and/or tumor diseases by inhibiting protein folding and protein breakdown
Zhou et al. PM2. 5 exposure and cold stress exacerbates asthma in mice by increasing histone acetylation in IL-4 gene promoter in CD4+ T cells
JP2012515213A5 (en)
UY30042A1 (en) NEW DERIVATIVES OF ALQUILFOSFOLÍPIDOS WITH REDUCED CYTOTOXICITY AND USES OF THE SAME.
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
Gao et al. An important role of interleukin-10 in counteracting excessive immune response in HT-29 cells exposed to Clostridium butyricum
NO20070854L (en) Human monoclonal antibodies to human IL-4.
YU55203A (en) Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
Li et al. Huaiqihuang may protect from proteinuria by resisting MPC5 podocyte damage via targeting p-ERK/CHOP pathway
Petito et al. Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis
Costa et al. ROS/RNS balancing, aerobic fermentation regulation and cell cycle control–a complex early trait (‘CoV-MAC-TED’) for combating SARS-CoV-2-induced cell reprogramming
BR112016000874A2 (en) genetically stable oncolytic rna virus, method of manufacture and use thereof
WO2006014864A3 (en) Methods and compositions for reducing c-reactive protein
BR112012026349A2 (en) new methods for isolating trl cells
WO2005005481A3 (en) Combination therapy for gastroenteric diseases caused by microorganisms
WO2008104062A3 (en) Selective release of pro-apoptotic bcl-2 family members and their contribution to the bystander effect
CY1112973T1 (en) FURTHER CRYSTAL FORMS OF ROSTAFOUROXIN
Zhang et al. Double bacteria synergistic catalytic reduction system for heavy metal detoxification treatment
DK1537204T3 (en) Granzym B as HSP70 / HSP70 peptide-dependent triggers of programmed cell death in tumor cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08714682

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08714682

Country of ref document: EP

Kind code of ref document: A2